B · Normal
[BeiGene: Plans to invest US$19.5 million in Bravera's Series A financing] On November 16, BeiGene (688235.SH) announced that the company's wholly-owned subsidiary BeiGene Switzerland plans to participate in BraveraBio's Series A financing together with related party BakerBros entities and other investors. BeiGene Switzerland is expected to invest a total of US$19.5 million in cash and convert its US$500,000 SAFE equity into Series A preferred shares. After the completion of this transaction, BeiGene Switzerland will hold 9.477% of Bravera shares. This transaction constitutes a related transaction, but does not constitute a major asset reorganization and does not need to be submitted to the board of directors and shareholders' meeting for review.
Comments